{"entity":{"id":"nct05000294","kind":"trial","name":"Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types","aka":[],"tldr":"A phase 1/2 trial of atezolizumab and tivozanib in gallbladder cancer, run by University of Florida, now recruiting.","summary":"Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types is a phase 1/2 interventional study registered as NCT05000294 by University of Florida, with a registry enrolment figure of 29 participants, started 2021-12-07 and due to reach its primary completion in 2026-12. Interventions recorded: Atezolizumab, Tivozanib. Conditions listed: Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Vulvar Cancer, Prostate Cancer. Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05000294","url":"https://clinicaltrials.gov/study/NCT05000294"}],"tags":["ctgov-ingest","gallbladder-deep-dive"],"related":[],"cancers":["gallbladder","cholangiocarcinoma"],"sections":[],"technologies":["checkpoint-inhibitor","kinase-inhibitors"],"targets":[],"drugs":["atezolizumab","tivozanib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05000294","phase":"1/2","setting":"Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types","sponsor":"University of Florida","participation":[{"nct":"NCT05000294","source":"https://clinicaltrials.gov/study/NCT05000294","fetchedAt":"2026-10-07T16:53:32.028Z","studySha256":"7eb46bcb3c8732c2eac787295d3b2a87a2f3c951b6e05eced90a064d7c8804a4","overallStatus":"RECRUITING","lastUpdatePosted":"2026-07-13","leadSponsor":"University of Florida","collaboratorCount":2,"minimumAge":"18 Years","maximumAge":"99 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":29,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["United States"]}],"started":"2021-12-07","startedType":"actual","enrolled":29,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05000294/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"tivozanib","kind":"drug","name":"Tivozanib","route":"/drugs/tivozanib/"}],"term":[{"id":"gallbladder-cancer-in-biliary-trials","kind":"term","name":"Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)","route":"/terms/gallbladder-cancer-in-biliary-trials/"}]}}